Companies
Shionogi
Targeted therapies — Off-target mitigation.
- Country
- Japan
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $482 million contract from U.S. government (Project BioShield) for domestic manufacturing of Fetroja | pharmexec.com |
| Revenue | 438.3 billion yen for fiscal year 2024 | shionogi.com |
| Headcount | 5,485 employees (global consolidation) as of March 31, 2024 | shionogi.com |
| Production site | Amagasaki, Tokushima, and Kanegasaki (Shionogi Pharma) | shionogi-ph.co.jp |
| Capacity | Production units ranging from desk-top (0.2kg/hr) to commercial size (5kg/hr) and medium/large manufacturing (>500kg) | shionogi-ph.co.jp · shionogi.com |
Independent sources: pharmexec.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Anti-AMR antibiotics | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.